Here's why Sirtex Medical Limited soared today

Yesterday proved to be a great time to buy shares of biotech heavyweight, Sirtex Medical Limited (ASX:SRX).

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you blinked you could have missed it…

After plummeting more than 55% yesterday, shares of biotechnology heavyweight Sirtex Medical Limited (ASX: SRX) today soared as much as 30% in afternoon trade.

After popping out of its trading halt yesterday morning, Sirtex Medical shares quickly dropped from their previous close price of $39.00 to a low of $15.12, following the release of what appeared to be terrible clinical trial result for its flagship liver cancer drug.

However, whilst the technology did not show a statistically significant improvement in overall Progression-Free Survival, the SIRFLOX trial did show a statistically significant improvement in Progression-Free Survival in the liver.

This small nugget of positive news is likely the reason investors have once again jumped on the Sirtex bandwagon.

Detailed analysis of the SIRFLOX study will be submitted to the American Society of Clinical Oncology's (ASCO) Annual Meeting in Chicago, which will be held between May 29 and June 2 this year.

A better bet than Sirtex Medical…

My advice is to wait until the dust settles over Sirtex Medical shares and until management provide further guidance to investors in coming months. Whilst it could be tempting to try and get in and out of the stock, to a make a quick buck, it's important to remember long-term investing is about time in the market, not timing the market.

Motley Fool Contributor Owen Raszkiewicz does not have a financial interest in any of the companies mentioned. Owen welcomes your feedback on Google plus (see below) or you can follow him on Twitter @ASXinvest. The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead.  This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »